OMENTIN-1 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: RELATION TO ATHEROGENESIS
DOI:
https://doi.org/10.21856/j-PEP.2015.2.02Keywords:
omentin-1, type 2 diabetes mellitus, adipokines, atherogenesis.Abstract
61 patients with type 2 diabetes mellitus (m/f: 34/27, disease duration 6.29 ± 0.67 years) with suboptimal or poor glycemic control, overweight or obese, with coronary heart disease and/or hypertension were observed. There were no significant changes in the concentration of circulating omentin-1 with respect to control individuals as well as in groups with the presence/absence of symptomatic coronary heart disease. The patients had no functional relation between the omentin-1 and parameters of carbohydrate/lipid dismetabolism. It was revealed complex relationship of normal omentin-1 levels and proinflammatory (interleukin-1β, inverse) and pro-atherogenic (osteoprotegerin, fetuin A, direct) components of cardiovascular risk, which proves the compensatory nature of this adipokine influence on vascular complications in type 2 diabetes
References
Blüher M, Mantzoros CS. Metabolism 2015; 64(1): 131-145.
Blüher M. Mol Metab 2014; 3: 230-240.
Yang R, Xu A, Pray J, et al. Diabetes 2003; 1:A1.
Xiang K, Wang Y, Zheng T, et al. Diabetes 2004; 53(1):228-234.
Schaffler A, Neumeier M, Herfarth H, et al. Biochim Biophys Acta 2005; 1732(1-3): 96-102.
Fain JN, Sacks HS, Buehrer B, et al. Int J Obes 2008; 32(5): 810-815.
Yang RZ, Lee MJ, Hu H, et al. Am J Physiol Endocrinol Metab 2006; 290(6): E1253-1261.
De Souza Batista CM, Yang RZ, Lee MJ, et al. Diabetes 2007; 56(6): 1655-1661.
Tan BK, Adya R, Farhatullah S, et al. Diabetes 2008; 57(4): 801-808.
Pan HY, Guo L, Li Q. Diab Res Clin Pract 2010; 88(1): 29-33.
Zhang Q, Zhu L, Zheng M, et al. Ann Endocrinol (Paris) 2014; 75(3): 171-175.
Shibata R, Ouchi N, Takahashi R, et al. Diabetol Metab Syndrome 2012; 4: 37.
Yoo HJ, Hwang SY, Hong HC, et al. Cardiovasc Diabetol 2011; 10(103): 1-8.
Liu R, Wang X, Bu P. Diab Res Clin Pract 2011; 93(1): 21-25.
Yamawaki H. Biol Pharm Bull 2011; 34(3):307-310.
Zhou JY, Chan L, Zhou SW. Curr Vasc Pharmacol 2014; 12(1): 136-143.
Matthews DR, Hosker JP, Rudenski AS, et al. Diabetologia 1985; 28: 412-419.
Katz A, Nambi SS, Mather K, et al. J Clin Endocrinol Metab 2000; 85: 2402-2410.
Flehmig G, Scholz M, Klöting N, et al. PLoS One 2014; 9(6): 1-14.
Kravchun NA, Poltorak VV, Grynchenko TS, et al. Kompleks profilaktychnyh zahodiv shhodo kardiovaskuljarnyh uskladnen’ ta cukrovogo diabetu 2 typu v grupah ryzyku i’h rozvytku: Metodychni rekomendacii’, Harkiv, 2010: 24 p.
Fietta P, Delsante G. Theor Biol Forum 2013; 106(1-2): 103-129.
Jialal I, Adams-Huet B, Duong F, Smith G. Metab Syndr Relat Dis 2014; 12(4): 227-230.
Collin-Osdoby P, Rothe L, Anderson F, et al. J Biol Chem 2001; 276: 20659-20672.
Hofbauer LC, Shui C, Riggs BL, et al. Biochem Biophys Res Commun 2001; 280: 334-339.
Collin-Osdoby P. Circ Res 2004; 95:1046-1057.
Avignon A, Sultan A, Piot C, et al. Diabetes Care 2007 ; 30: 3934-3939.
Gorshuns’ka MJu. Probl Endokryn Patologii’ 2012; 1:5-15.
Stefan N, Fritsche A, Weikert C, et al. Diabetes 2008; 57: 2762-2767.
Gorshuns’ka MJu, Karachencev JuI, Kravchun NO, et al. Ukr Biohim Zhurn 2013; 85(3): 5-16.
Saremi A, Asghari M, Ghorbani A. J Sports. Sci 2010; 28(9): 993-998.
Katsi V, Vamvakou G, Lekakis J, et al. Heart Lung Circ 2014; 23(9): 802-806.
Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T. Exp Clin Endocrinol Diab 2013; 121(7): 377-383.
ISSN 
ISSN 
